» Articles » PMID: 30315887

MicroRNA Expression Profiles in Upper Tract Urothelial Carcinoma Differentiate Tumor Grade, Stage, and Survival: Implications for Clinical Decision-Making

Overview
Journal Urology
Specialty Urology
Date 2018 Oct 14
PMID 30315887
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To evaluate microRNA (miRNA) biomarkers for upper tract urothelial carcinoma (UTUC) to improve risk stratification.

Methods: miRNA was isolated from 157 radical nephroureterectomy specimens from 2 institutions. The relative expression of miRNA was examined for high grade vs low grade tumors as well as muscle invasive vs nonmuscle invasive tumors. Recurrence free survival (RFS) and overall survival (OS) were also stratified using relative expression of specific miRNA.

Results: The optimized model to identify high grade UTUC included miR-29b-2-5p, miR-18a-5p, miR-223-3p, and miR-199a-5p, generating a sensitivity of 83%, specificity of 85%, and generated a receiver operating characteristic (ROC) curve with area-under-the-curve of 0.86. Similarly, the model classifier for predicting ≥pT2 disease incorporated miR-10b-5p, miR-26a-5p-5p, miR-31-5p, and miR-146b-5p, producing a sensitivity of 64%, specificity of 96%, and area-under-the-curve of 0.90. RFS was best reflected by a combination of miR-10a-5p, miR-30c-5p, and miR-10b-5p, while OS was best predicted by miR-10a-5p, miR-199a-5p, miR-30c-5p, and miR-10b-5p.

Conclusion: High-grade vs low-grade as well as muscle invasive vs nonmuscle invasive UTUC can be reliable distinguished with unique miRNA signatures. Furthermore, differential expression of UTUC miRNA produces robust classifiers for predicting RFS and OS that may help identify patients who would most benefit from adjuvant therapies.

Citing Articles

Diagnostic status and new explorations in upper urinary tract urothelial carcinoma: a literature review.

Shan Z, Deng X, Yang L, Zhang G Transl Androl Urol. 2024; 13(11):2570-2586.

PMID: 39698558 PMC: 11650341. DOI: 10.21037/tau-24-326.


Clinical Implications of the Molecular and Genomic Landscape of Upper Tract Urothelial Carcinoma.

Jaime-Casas S, Tripathi A, Pal S, Yip W Curr Urol Rep. 2024; 26(1):11.

PMID: 39379745 PMC: 11461588. DOI: 10.1007/s11934-024-01245-1.


MicroRNAs in Genitourinary Malignancies: An Exciting Frontier of Cancer Diagnostics and Therapeutics.

Kathuria-Prakash N, Dave P, Garcia L, Brown P, Drakaki A Int J Mol Sci. 2024; 25(17).

PMID: 39273446 PMC: 11394927. DOI: 10.3390/ijms25179499.


MicroRNA Signatures in the Upper Urinary Tract Urothelial Carcinoma Scenario: Ready for the Game Changer?.

Cinque A, Capasso A, Vago R, Floris M, Lee M, Minnei R Int J Mol Sci. 2022; 23(5).

PMID: 35269744 PMC: 8910117. DOI: 10.3390/ijms23052602.


MicroRNA-375-3p Suppresses Upper Tract Urothelial Carcinoma Cell Migration and Invasion via Targeting Derlin-1.

Jhan J, Hsu W, Lee Y, Li W, Huang A, Lin H Cancers (Basel). 2022; 14(4).

PMID: 35205628 PMC: 8869792. DOI: 10.3390/cancers14040880.